4 Stocks Raising The Health Services Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 81 points (0.5%) at 15,076 as of Thursday, June 13, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,136 issues advancing vs. 827 declining with 99 unchanged.

The Health Services industry currently sits up 0.4% versus the S&P 500, which is up 0.6%. Top gainers within the industry include Edwards Life ( EW), up 3.5%, Medtronic ( MDT), up 1.4%, Covidien ( COV), up 1.3%, Smith & Nephew ( SNN), up 1.1% and HCA Holdings ( HCA), up 0.9%. On the negative front, top decliners within the industry include St Jude Medical ( STJ), down 0.58, and DaVita HealthCare Partners ( DVA), down 0.60.

TheStreet Ratings group would like to highlight 4 stocks pushing the industry higher today:

4. C.R. Bard ( BCR) is one of the companies pushing the Health Services industry higher today. As of noon trading, C.R. Bard is up $2.62 (2.49) to $107.73 on average volume Thus far, 332,910 shares of C.R. Bard exchanged hands as compared to its average daily volume of 636,100 shares. The stock has ranged in price between $105.18-$107.77 after having opened the day at $105.30 as compared to the previous trading day's close of $105.11.

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. C.R. Bard has a market cap of $8.4 billion and is part of the health care sector. The company has a P/E ratio of 18.6, above the S&P 500 P/E ratio of 17.7. Shares are up 7.5% year to date as of the close of trading on Wednesday. Currently there are 5 analysts that rate C.R. Bard a buy, 2 analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates C.R. Bard as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full C.R. Bard Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Quest Diagnostics ( DGX) is up $0.77 (1.24) to $62.77 on light volume Thus far, 501,710 shares of Quest Diagnostics exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $61.71-$62.93 after having opened the day at $62.00 as compared to the previous trading day's close of $62.00.

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. Quest Diagnostics has a market cap of $9.9 billion and is part of the health care sector. The company has a P/E ratio of 17.0, below the S&P 500 P/E ratio of 17.7. Shares are up 6.4% year to date as of the close of trading on Wednesday. Currently there is 1 analyst that rates Quest Diagnostics a buy, 2 analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Quest Diagnostics Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Stryker Corporation ( SYK) is up $0.49 (0.74) to $66.86 on light volume Thus far, 220,136 shares of Stryker Corporation exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $65.81-$66.89 after having opened the day at $66.32 as compared to the previous trading day's close of $66.37.

Stryker Corporation, a medical technology company, provides reconstructive, medical and surgical, and neurotechnology and spine products for doctors, hospitals, and other healthcare facilities. Stryker Corporation has a market cap of $25.3 billion and is part of the health care sector. The company has a P/E ratio of 20.4, above the S&P 500 P/E ratio of 17.7. Shares are up 21.1% year to date as of the close of trading on Wednesday. Currently there are 14 analysts that rate Stryker Corporation a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Stryker Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Stryker Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Baxter International ( BAX) is up $0.43 (0.62) to $70.18 on light volume Thus far, 862,526 shares of Baxter International exchanged hands as compared to its average daily volume of 3.5 million shares. The stock has ranged in price between $68.82-$70.38 after having opened the day at $69.51 as compared to the previous trading day's close of $69.75.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $37.8 billion and is part of the health care sector. The company has a P/E ratio of 16.9, below the S&P 500 P/E ratio of 17.7. Shares are up 4.6% year to date as of the close of trading on Wednesday. Currently there are 14 analysts that rate Baxter International a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Baxter International Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Dow Rises Sharply as U.S.-China Trade Tensions Thaw

Dow Rises Sharply as U.S.-China Trade Tensions Thaw

Apple Shares Gain as U.S. and China Call Off Trade War, For Now

Apple Shares Gain as U.S. and China Call Off Trade War, For Now

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec

Treasury Secretary Mnuchin: 'Take the Over' on U.S. GDP Topping 3% This Year

Treasury Secretary Mnuchin: 'Take the Over' on U.S. GDP Topping 3% This Year

Video: Why the Stock Market Is Discounting China Trade Fears for Now

Video: Why the Stock Market Is Discounting China Trade Fears for Now